glp-1 weight loss drug news november 2025 Retailers across the country are noticing a spike in returns of clothing as more Americans embrace drugs for loss. The rate of retail exchanges where shoppers traded clothing for a The GLP-1 Access Gap: Mapping
Description
Dulaglutide is less likely to cause injection site reactions (0.5%) than most other GLP analogs (although Ozempic is lower at 0.2%)
Notably, more than 80% of those who used to take a treatment were only on a therapy for 12 months or less
48 24 22.5%
Andreazza AC, Duong A, Young LT
That flexibility, combined with the weight loss guarantee, makes Shed appealing for people who want options and a safety net
The litigation currently focuses on semaglutide and tirzepatide products
